Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Apr 27;8(2):127–136. doi: 10.1007/s11523-013-0271-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2013

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

PMC Copyright notice

Fig. 1 — a 20020408 Study Schema, b CONSORT diagram, c groups included in the primary post hoc analysis that compared patients with MT KRAS (n = 84) and WT KRAS (n = 124) tumors who received panitumumab versus patients with MT KRAS (n = 100) tumors who received BSC alone. d Groups included in the second post hoc analysis that compared patients with WT KRAS (n = 124) tumors who received panitumumab versus patients with MT KRAS (n = 100) tumors who received BSC alone. e Groups included in the third post hoc analysis that compared patients with WT KRAS tumors who received panitumumab (n = 124) and BSC alone (n = 119) versus patients with MT KRAS tumors who received panitumumab (n = 84) and BSC alone (n = 100)

Fig. 1 — a 20020408 Study Schema, b CONSORT diagram, c groups included in the primary post hoc analysis that compared patients with MT KRAS (n = 84) and WT KRAS (n = 124) tumors who received panitumumab versus patients with MT KRAS (n = 100) tumors who received BSC alone. d Groups included in the second post hoc analysis that compared patients with WT KRAS (n = 124) tumors who received panitumumab versus patients with MT KRAS (n = 100) tumors who received BSC alone. e Groups included in the third post hoc analysis that compared patients with WT KRAS tumors who received panitumumab (n = 124) and BSC alone (n = 119) versus patients with MT KRAS tumors who received panitumumab (n = 84) and BSC alone (n = 100)